Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

Wilkins, 1959, New drugs for the treatment of hypertension, Ann Intern Med, 50, 1, 10.7326/0003-4819-50-1-1 Goldner, 1960, Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus, N Engl J Med, 262, 403, 10.1056/NEJM196002252620807 Hollis, 1961, Aggravation of diabetes mellitus during treatment with chlorothiazide, JAMA, 176, 947, 10.1001/jama.1961.63040240013020 Samaan, 1963, Diabetogenic action of benzothiadiazines: serum insulin-like activity in diabetes worsened or precipitated by thiazide diuretics, Lancet, 47, 1244, 10.1016/S0140-6736(63)90893-6 Luna, 2001, Drug-induced hyperglycemia, JAMA, 286, 1945, 10.1001/jama.286.16.1945 Scheen, 2004, Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system, Drugs, 64, 2537, 10.2165/00003495-200464220-00004 Gurwitz, 1992, Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus, Ann Intern Med, 118, 273, 10.7326/0003-4819-118-4-199302150-00005 Gress, 2000, Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus, N Engl J Med, 342, 905, 10.1056/NEJM200003303421301 Taylor, 2006, Antihypertensive medications and the risk of incident type 2 diabetes, Diabetes Care, 29, 1065, 10.2337/dc05-2366 Bengtsson, 1984, Do antihypertensive drugs precipitate diabetes?, BMJ, 289, 1495, 10.1136/bmj.289.6457.1495 Pollare, 1989, A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension, N Engl J Med, 321, 868, 10.1056/NEJM198909283211305 Opie, 2004, Old antihypertensives and new diabetes, J Hypertens, 22, 1453, 10.1097/01.hjh.0000133732.24501.9e Padwal, 2004, Antihypertensive therapy and incidence of type 2 diabetes, Diabetes Care, 27, 247, 10.2337/diacare.27.1.247 Padwal, 2005, A systematic review of drug therapy to delay or prevent type 2 diabetes, Diabetes Care, 28, 736, 10.2337/diacare.28.3.736 Scheen, 2004, Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: part 1: a meta-analysis of randomised clinical trials, Diabetes Metab, 30, 487, 10.1016/S1262-3636(07)70146-5 Abuissa, 2005, Angiotensin-converting enyzme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials, J Am Coll Cardiol, 46, 821, 10.1016/j.jacc.2005.05.051 Gillespie, 2005, The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes, Diabetes Care, 28, 2261, 10.2337/diacare.28.9.2261 Jandeleit-Dahm, 2005, Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes, J Hypertens, 23, 463, 10.1097/01.hjh.0000160198.05416.72 Elliott, 2005, Differential effects of antihypertensive drugs on new-onset diabetes?, Curr Hypertens Rep, 7, 249, 10.1007/s11906-005-0021-4 Liu, 2005, for the FEVER Study Group. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients, J Hypertens, 23, 2157, 10.1097/01.hjh.0000194120.42722.ac Lumley, 2002, Network meta-analysis for indirect treatment comparisons, Stat Med, 21, 2313, 10.1002/sim.1201 Vermes, 2003, Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies of Left Ventricular Dysfunction (SOLVD), Circulation, 107, 1291, 10.1161/01.CIR.0000054611.89228.92 Bakris, 2006, Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome, Diabetes Care, 29, 2592, 10.2337/dc06-1373 Julius, 2006, Feasibility of treating prehypertension with an angiotensin-receptor blocker, N Engl J Med, 354, 1685, 10.1056/NEJMoa060838 Thornley-Brown, 2006, Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease, Arch Intern Med, 166, 797, 10.1001/archinte.166.7.797 2002, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 288, 2981, 10.1001/jama.288.23.2981 Lindholm, 2003, Metabolic outcome during 1 year in a newly-detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE Study), J Hypertens, 21, 1563, 10.1097/00004872-200308000-00022 Dahlöf, 2005, Lancet, 366, 895, 10.1016/S0140-6736(05)67185-1 Hansson, 1999, Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial, Lancet, 353, 611, 10.1016/S0140-6736(98)05012-0 Yusuf, 2005, Effects of candesartan on the development of a new diagnosis of diabetes in patients with heart failure, Circulation, 112, 48, 10.1161/CIRCULATIONAHA.104.528166 2006, Effect of ramipril on the incidence of diabetes, N Engl J Med, 355, 1551, 10.1056/NEJMoa065061 Fletcher, 1991, Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly, J Hypertens, 9, 225, 10.1097/00004872-199103000-00005 Wilhelmsen, 1987, Beta-blockers versus diuretics in hypertensive men: main result from the HAPPHY trial, J Hypertens, 5, 560, 10.1097/00004872-198710000-00009 Yusuf, 2001, Ramipril and the development of diabetes, JAMA, 286, 1882, 10.1001/jama.286.15.1882 Brown, 2000, Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT), Lancet, 356, 366, 10.1016/S0140-6736(00)02527-7 Pepine, 2003, A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial, JAMA, 290, 2805, 10.1001/jama.290.21.2805 Dahlöf, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3 1992, Medical Research Council trial of treatment of hypertension in older adults: principal results, BMJ, 304, 405, 10.1136/bmj.304.6824.405 Hansson, 2000, Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study, Lancet, 356, 359, 10.1016/S0140-6736(00)02526-5 2004, Angiotensin-converting-enzyme inhibition in stable coronary artery disease, N Engl J Med, 351, 2058, 10.1056/NEJMoa042739 Lithell, 2003, The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial, J Hypertens, 21, 875, 10.1097/00004872-200305000-00011 Savage, 1998, Influence of long-term, low-dose, diuretic-based antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension, Arch Intern Med, 158, 741, 10.1001/archinte.158.7.741 Hansson, 1999, Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study, Lancet, 354, 1751, 10.1016/S0140-6736(99)10327-1 Julius, 2004, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial, Lancet, 363, 2022, 10.1016/S0140-6736(04)16451-9 Appel, 2002, The verdict from ALLHAT: thiazide diuretics are the preferred initial therapy for hypertension, JAMA, 288, 3039, 10.1001/jama.288.23.3039 Psaty, 2006, Recent trials in hypertension: compelling science or commercial speech?, JAMA, 295, 1704, 10.1001/jama.295.14.1704 Psaty, 2003, Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis, JAMA, 289, 2534, 10.1001/jama.289.19.2534 Pfeffer, 2003, Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme, Lancet, 362, 759, 10.1016/S0140-6736(03)14282-1 2005, Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE Study extension, Circulation, 112, 1339, 10.1161/CIRCULATIONAHA.105.548461 Kostis, 2005, Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes, Am J Cardiol, 95, 29, 10.1016/j.amjcard.2004.08.059 Prisant, 2004, Preventing type II diabetes mellitus, J Clin Pharmacol, 44, 406, 10.1177/0091270004263018 Kurtz, 2004, Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system, J Hypertens, 22, 2253, 10.1097/00004872-200412000-00003 2004, Position statement: diagnosis and classification of diabetes mellitus, Diabetes Care, 27, S5 Bakris, 2004, Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial, JAMA, 292, 2227, 10.1001/jama.292.18.2227 Lindholm, 2002, Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study, J Hypertens, 20, 1879, 10.1097/00004872-200209000-00035 Chobanian, 2003, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2 2006, Hypertension: management of hypertension in adults in primary care, a partial update of NICE clinical guideline 18 Verdecchia, 2004, Adverse prognostic significance of new diabetes in treated hypertensive subjects, Hypertension, 43, 963, 10.1161/01.HYP.0000125726.92964.ab Qiao, 2003, Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up, Diabetes Care, 26, 2910, 10.2337/diacare.26.10.2910 Teo, 2004, Am Heart J, 148, 52, 10.1016/j.ahj.2004.03.020